Our comprehensive cell therapy platform was designed to generate allogeneic, iPSC-derived NK and T cell products for the treatment of both hematological and solid tumor malignancies with significant unmet medical need.
We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies.
Century’s approach builds on a foundation of proven allogenic and autologous therapy research to transform cell therapy as we know it today.
Century Core Competencies
We have developed highly efficient gene engineering processes to generate our product candidates. We are currently using the CRISPR-MAD7 nuclease to enable precise cutting of the iPSC genome, and have developed proprietary applications of the CRISPR-MAD7 technology to genetically modify iPSCs by simultaneously removing target genes or adding transgenes of interest at precise genetic loci. Our approach preserves genome integrity and achieves more predictable and consistent transgene expression as compared to approaches driven by viruses or transposable segments called transposons, which result in varied gene copy number and random integration events that risk mutations, namely insertional mutagenesis.
We are leveraging our Allo-EvasionTM technology to design cells capable of evading identification and destruction by the host immune system, which may permit dosing in patients with limited or no immune preconditioning regimens. The technology was designed to reduce allogeneic immune-reactivity, thereby potentially helping to prevent rejection by the patient’s immune system, allowing repeat dosing of our CAR-modified cell therapies and sustaining therapeutic efficacy over a long period of time.
CAR design is a critical component of innovative cell therapy product candidates. We believe that targeting multiple antigens on tumor cells will help address tumor heterogeneity and antigen loss, which are frequently observed in tumor cells. We have created a proprietary synthetic library to enable in-house binder screens and multiple campaigns against several tumor antigens are ongoing to generate the CAR constructs for future product candidates.
Century is uniquely able to accelerate new product candidate generation by bulk editing progenitor cells to share a core set of common features that increase their functionality, safety and persistence. We believe this approach will significantly shorten the time required to develop subsequent product candidates, unlike existing cell therapy platforms, which require making individual gene engineering steps – a time and resource intensive process.
We believe our use of iPSCs, which have the potential to propagate indefinitely, will allow us to develop a streamlined manufacturing process with scalability advantages while producing consistent, high quality, off-the-shelf products at reduced manufacturing costs. Given the indefinite propagation potential of iPSC-derived allogeneic cells, we believe that a single master cell bank can be used for the lifetime of the product.